Feb 4, 2025

BillionToOne, a next-generation molecular diagnostics company, announced record financial results during this year’s J.P. Morgan Healthcare Conference in San Francisco. Last year, the company’s revenue reached $153 million, which is more than doubling from $72 million in 2023. BillionToOne’s success was driven primarily by its prenatal testing business, which has captured an estimated 15% market share in the U.S. Building on the success in prenatal testing, BillionToOne is now accelerating its expansion into the oncology liquid biopsy market for late-stage cancers, estimated at $20+ billion, supported by a $130 million Series D financing round secured last summer. And the company’s Northstar Select and Northstar Response assays, designed for therapy selection and treatment response monitoring, have demonstrated superior detection capabilities. For example, Northstar Select identified 51% more single nucleotide variants than competing solutions while doubling the detection of copy number variants, as presented at the latest ASCO Conference. Launched in 2023, Northstar made significant commercial progress this year and surpassed 3,000 ordered tests in Q4 alone. BillionToOne is also developing a tumor-naive minimal residual disease test. The company, which currently employs more than 500 people, plans to expand its workforce by at least 100 new employees throughout 2025 to support continued growth. KEY QUOTE: “We saw strong momentum in our prenatal business during 2024, with tremendous revenue growth and profitability in the fourth quarter. We have achieved robust prenatal business growth with a fraction of the sales force size of our largest competitor, demonstrating the power of our technology and differentiation that our products have.” Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne Pulse 2.0 focuses on business news, profiles, and deal flow coverage.